FDA shakes up weight loss market
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold unbranded copies of those drugs are mounting a coordinated effort to reverse this decision,
Mounjaro will soon be available as a weight loss treatment on the NHS. Here's what that means for patients
The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to proposals made by the National Institute for Health and Care Excellence (Nice). Previously,
Weight-loss drug Wegovy to hit market on Tuesday
Weight-loss drug Wegovy will go on sale in Korea on Tuesday, with the much-anticipated injectable drug available for order through Zeullig Pharma Korea.
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
Tirzepatide: what is weight loss injection Mounjaro, what have the experts said - how is different to Ozempic?
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and content measurement, audience insights and product development. List of Partners (vendors)
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
Teens With Obesity Less Likely to Be Suicidal on Weight Loss Drugs: Study
Weight loss drugs like Ozempic were associated with a lower risk of suicidal thoughts in teens with obesity, a new study found.
The weight loss drug with a waitlist
Sky News has revealed thousands of people with severe obesity are being denied access to effective treatment, partly because of a slow NHS rollout of the weight loss jab Wegovy.
Weight loss drugs have one big issue; These companies want to fix it
Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
STAT3d
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...
Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers
Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...
STAT2d
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...